Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB Net Income
Bottom-line profit after all expenses, interest, and taxes.
Core Laboratories N.V.NYSE: CLB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$789K, compared with -$154K a year earlier. Trailing-twelve-month net income was $29.03M. Over 3 fiscal years it compounded at +15.1% a year.
Context
- Net income amounted to 5.6% of revenue in FY2025, down 0.4 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of $21.88M (-26.2%) for the fiscal year ending Dec 2026, a slowdown from the -5.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$789K-115.9% QoQ
- Last fiscal yearDec 2025
- $29.67M-5.5% YoY
- LTMMar 2026
- $29.03M+3.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -412.3% | -61.8% | +350.5 pp |
| 1 year | -5.5% | -26.2% | -20.7 pp |
| 3-year CAGR | +15.1% | +12.3% | -2.8 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 29.67M USD
- Year-over-year change
- -5.5%
- 4-year CAGR
- +10.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.67M | -5.5% |
| FY2024 | 2024-12-31 | 31.4M | -14.4% |
| FY2023 | 2023-12-31 | 36.68M | +88.5% |
| FY2022 | 2022-12-31 | 19.45M | -1.4% |
| FY2021 | 2021-12-31 | 19.73M | — |
Net Income vs competitors
How CLB compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +3.6% is the 4th highest of 10, against a peer median of -114.0%.
- Net income amounts to 5.5% of revenue for CLB, versus a peer median of 7.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $207.97M USD | +291.2% | — | 6.4% | |
| LTM Mar 2026 | $56.89M USD | +91.8% | -12.3% | 1.6% | |
| LTM Mar 2026 | $35.9M USD | -29.3% | — | 3.4% | |
| LTM Mar 2026 | $29.03M USD | +3.6% | +15.1% | 5.5% | |
| LTM Mar 2026 | -CA$15.29M CAD | -114.0% | — | 0.8% | |
| LTM Mar 2026 | -$19.67M USD | -175.9% | -40.3% | 7.1% | |
| LTM Mar 2026 | -$32.49M USD | -363.2% | -54.7% | 7.1% | |
| LTM Mar 2026 | -$98.37M USD | -728.8% | — | 27.7% | |
| LTM Mar 2026 | -$144.82M USD | -215.9% | -56.9% | 18.8% | |
| LTM Mar 2026 | -$497.64M USD | +9.0% | — | 39153.7% | |
| Peer median (excluding CLB) | — | -114.0% | -47.5% | 7.1% | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 470.25M | 489.74M | 509.79M | 523.85M | 526.52M |
| Cost of Revenue | 386.41M | 410.82M | 415.74M | 435.48M | 432.24M |
| Gross Profit | 83.84M | 78.92M | 94.05M | 88.37M | 94.28M |
| Gross Margin | 17.8% | 16.1% | 18.4% | 16.9% | 17.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 44.17M | 38.12M | 38.89M | 38.59M | 44.23M |
| Operating Expenses | 38.58M | 37.4M | 39.41M | 29.82M | 43.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| EBITDA | 63.78M | 58.69M | 70.42M | 73.51M | 71.12M |
| EBITDA Margin | 13.6% | 12.0% | 13.8% | 14.0% | 13.5% |
| Operating Income | 45.26M | 41.52M | 54.64M | 58.56M | 50.49M |
| Operating Margin | 9.6% | 8.5% | 10.7% | 11.2% | 9.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.15M | 11.57M | 13.43M | 12.37M | 10.57M |
| Other Income / Expenses | (9.15M) | (11.57M) | (13.43M) | (12.37M) | (4.59M) |
| Income Before Tax | 36.11M | 29.95M | 41.21M | 46.19M | 45.9M |
| Pre-Tax Margin | 7.7% | 6.1% | 8.1% | 8.8% | 8.7% |
| Income Tax Expense | 15.89M | 10.3M | 4.19M | 14.03M | 15.51M |
| Net Income | 19.73M | 19.45M | 36.68M | 31.4M | 29.67M |
| Net Margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% |
| EPS (Basic) | 0.43 | 0.42 | 0.79 | 0.67 | 0.68 |
| EPS (Diluted) | 0.42 | 0.42 | 0.77 | 0.66 | 0.68 |
| Weighted Avg Shares | 46.01M | 46.33M | 46.68M | 46.9M | 46.5M |
| Weighted Avg Shares (Diluted) | 46.69M | 46.81M | 47.52M | 47.69M | 46.5M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.